 AbCellera Biologics Inc NASDAQ: ABCL has entered into a research collaboration and license agreement with Moderna Inc NASDAQ: MRNA for antibodies for mRNA medicines. The collaboration will leverage AbCelleras AI-powered technology to search and analyze natural immune responses to identify therapeutic antibodies against up to six targets selected by Moderna. 